BFRI
Biofrontera Inc

8,669
Mkt Cap
$9.88M
Volume
290,135.00
52W High
$1.19
52W Low
$0.536
PE Ratio
-0.72
BFRI Fundamentals
Price
$0.8483
Prev Close
$0.87
Open
$0.8722
50D MA
$0.8743
Beta
0.63
Avg. Volume
932,620.79
EPS (Annual)
-$1.04
P/B
0.94
Rev/Employee
$453,315.22
$5.56
Loading...
Loading...
News
all
press releases
Biofrontera (BFRI) Q4 2025 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·5d ago
News Placeholder
More News
News Placeholder
Are Medical Stocks Lagging Align Technology (ALGN) This Year?
Here is how Align Technology (ALGN) and Biofrontera Inc. (BFRI) have performed compared to their sector so far this year.
Zacks·13d ago
News Placeholder
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·15d ago
News Placeholder
Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Biofrontera Inc. (BFRI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·2mo ago
News Placeholder
Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year?
Here is how Biofrontera Inc. (BFRI) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Biofrontera Earnings Preview
read more...
Benzinga·4mo ago
News Placeholder
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -3.70% and -75.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of +3.33% and +16.60%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +58.54% and +50.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +116.81% and +20.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
<
1
2
...
>

Latest BFRI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.